Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) gapped down before the market opened on Thursday . The stock had previously closed at $0.96, but opened at $0.84. Sunesis Pharmaceuticals shares last traded at $0.81, with a volume of 6,041,285 shares trading hands.
SNSS has been the topic of several analyst reports. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, June 17th. Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Sunday, June 16th. Zacks Investment Research downgraded HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a report on Friday, May 24th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Sunesis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $3.08.
The firm has a 50 day simple moving average of $0.75. The company has a market cap of $53.67 million, a price-to-earnings ratio of -1.08 and a beta of 2.76.
Institutional investors have recently made changes to their positions in the company. Aisling Capital Management LP grew its stake in shares of Sunesis Pharmaceuticals by 192.3% in the first quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock worth $9,234,000 after acquiring an additional 5,000,000 shares during the last quarter. Fosun International Ltd acquired a new stake in shares of Sunesis Pharmaceuticals in the first quarter worth $863,000. Finally, Algert Global LLC acquired a new stake in shares of Sunesis Pharmaceuticals in the first quarter worth $25,000. Institutional investors and hedge funds own 43.10% of the company’s stock.
About Sunesis Pharmaceuticals (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Further Reading: What is a stock buyback?
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.